World Library  
Flag as Inappropriate
Email this Article


Article Id: WHEBN0034640421
Reproduction Date:

Title: Mavoglurant  
Author: World Heritage Encyclopedia
Language: English
Subject: Fragile X syndrome, LY-344,545, MMPIP, LY-307,452, PCCG-4
Publisher: World Heritage Encyclopedia


CAS number  YesY
Jmol-3D images Image 1
Molecular formula C19H23NO3
Molar mass 313.39 g mol−1
Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa)

Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome.[1] It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).[2]

Mavoglurant is under development by Novartis and is currently in Phase II and Phase III clinical trials.[1][3] Phase IIb/III dose finding and evaluation trials for fragile X-syndrome have been discontinued by the end of 2014. [4] Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.[5]
Mavoglurant is also in Phase II clinical trials for Levodopa-induced dyskinesia.[6][7]
In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.[8]
Currently Novartis is conducting a clinical trial with this drug on obsessive compulsive disorder.[9]

Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.[10]

See also


  1. ^ a b P. Cole (2012). "Mavoglurant". Drugs of the Future 37 (1): 7–12.  
  2. ^ Levenga, J; Hayashi, S; De Vrij, FM; Koekkoek, SK; Van Der Linde, HC; Nieuwenhuizen, I; Song, C; Buijsen, RA et al. (2011). "AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome". Neurobiology of disease 42 (3): 311–7.  
  3. ^ Jacquemont, S.; Curie, A.; Des Portes, V.; Torrioli, M. G.; Berry-Kravis, E.; Hagerman, R. J.; Ramos, F. J.; Cornish, K. et al. (2011). "Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome is Associated with Differential Response to the mGluR5 Antagonist AFQ056". Science Translational Medicine 3 (64): 64ra1.  
  4. ^
  5. ^ "AFQ056 drug improves symptoms in Fragile X patients: Study". January 9, 2011. 
  6. ^ "Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.". Int J Neurosci. Sep 2013.  
  7. ^ "NHI Clinical trials". 
  8. ^ "Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking". 
  9. ^ "Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD)". 
  10. ^ FRAXA (2014). "Novartis Discontinues Development of mavoglurant (AFQ056) for Fragile X Syndrome". 

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.